Peter Ansell
AbbVie (United States)(US)
Publications by Year
Research Areas
Glioma Diagnosis and Treatment, Lung Cancer Treatments and Mutations, PARP inhibition in cancer therapy, Cancer Genomics and Diagnostics, Colorectal Cancer Treatments and Studies
Most-Cited Works
- → Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer(2019)912 cited
- → Activation of p53 by MEG3 Non-coding RNA(2007)643 cited
- → The Effects of SOM230 on Cell Proliferation and Adrenocorticotropin Secretion in Human Corticotroph Pituitary Adenomas(2006)200 cited
- → Depatuxizumab mafodotin in EGFR-amplified newly diagnosed glioblastoma: A phase III randomized clinical trial(2022)138 cited
- → Efficacy of depatuxizumab mafodotin (ABT-414) monotherapy in patients with EGFR-amplified, recurrent glioblastoma: results from a multi-center, international study(2017)132 cited
- → Bio2RDF Release 2: Improved Coverage, Interoperability and Provenance of Life Science Linked Data(2013)130 cited
- → The ChEMBL database as linked open data(2013)128 cited
- → Efficacy and safety results of ABT-414 in combination with radiation and temozolomide in newly diagnosed glioblastoma(2016)110 cited
- → Phase 2 trial of linifanib (ABT‐869) in patients with unresectable or metastatic hepatocellular carcinoma(2012)107 cited
- → Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Protein–Overexpressing Advanced Nonsquamous EGFR -Wildtype Non–Small Cell Lung Cancer in the Phase II LUMINOSITY Trial(2024)105 cited